868 abstracts found.



Results filter

Design, synthesis and investigation of antitumour agents based on natural products

Year:

Session type:

Mark Searcey

School of Chemical Sciences & Pharmacy, University of East Anglia, UK


Lead optimisation of rapamycin mTOR inhibitors through biosynthetic engineering

Year:

Session type:

Barrie Wilkinson

Biotica, Cambridge, UK


A novel small molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vivo

Year:

Session type:

CR Ireson1, KB Harikumar2, AB Kunnumakkara2, A Deorukhkar2, Z Tong2, S Jamieson1, R Sutherland1, T Raynham1, M Charles1, A Bagherzadeh1, M Farooq1, D Maru2, P Diagaradjane2, Y Matsuo2, S Krishnan2, J Gelovani2, BB Aggarwal2, S Guha2

1Wolfson Institute for Biomedical Research, London, UK, 2The UT MD Anderson Cancer Center, Houston, USA


Advances in the management of neuroendocrine tumours

Year:

Session type:

Martyn Caplin

The Royal Free Hospital, London, UK


Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicentre, randomised phase III trial (the UK ABC-02 trial)

Year:

Session type:

Juan Valle1, Harpreet S Wasan2, Daniel D Palmer3, David Cunningham4, Allan Anthoney5, Anthony Maraveyas6, Sharon Hughes7, Michael Roughton7, John Bridgewater7

1Christie Hospital NHS Trust, Manchester, UK, 2Imperial College Healthcare Trust, London, UK, 3University of Birmingham, UK, 4Royal Marsden Hospital, London, UK, 5St. James' University Hospital, Leeds, UK, 6Castle Hill Hospital, Hull, UK, 7University College London, UK


Pharmacokinetic and pharmacodynamic Phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition

Year:

Session type:

Shahneen Sandhu1, Tim Yap1, Nina Tunariu1, Martyn Lolkema1, Daniel Tan1, Andre Brunetto1, Rebecca Kristeleit1, Salma Alam1, L Rhoda Molife1, Joyce Kapawa1, Michael Germuska2, Edward Garmey3, Feng Chai3, James Li3, Stan B Kaye1, Nandita deSouza1, Johann S de Bono1

1Royal Marsden NHS Foundation Trust, Sutton, UK, 2The Institute of Cancer Research, Drug Development Unit, Sutton, UK, 3ArQule Inc, Woburn, Massachusetts, USA


Randomised controlled trial of Early Enteral Nutrition (EEN) versus Conventional Management (CON) in patients undergoing major resection for upper gastrointestinal cancer

Year:

Session type:

Rachael Barlow1, Wyn Lewis2, Geoff Clarke2, Sarah Hunt1, Tim Harvard2, Malcolm Puntis1, Tricia Price1

1Cardiff University, Cardiff, UK, 2Cardiff and Vale NHS Trust, Cardiff, UK


The second anal cancer trial (ACT2): a randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus

Year:

Session type:

David Sebag-Montefiore, Rob Glynne-Jones, Helen Meadows, Susan Wan, Latha Kadalayil, John Northover, David Cunningham, Jonathan Lederman, Roger James

On behalf of the National Cancer Research Institute and the 2nd Anal Cancer Trial Management Group, University College Clinical Trial Unit, London, UK


A microRNA prognostic signature for pancreatic ductal adenocarcinoma

Year:

Session type:

Nigel Jamieson2, Ross Carter1, Colin McKay1, Nicol Keith2, Karin Oien2

1West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, UK, 2University of Glasgow, UK


ESPAC-3(v2): a multicentre, international, open label, randomised controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma

Year:

Session type:

J Neoptolemos, M Bchler, D D Stocken, P Ghaneh, D Smith, C Bassi, M Moore, D Cunningham, C Dervenis, D Goldstein

For the ESPAC Group. University of Liverpool; University of Heidelberg; University of Birmingham; Clatterbridge Centre for Oncology; University of Verona; Princess Margaret Hospital, Toronto; Royal Marsden Hospital; Agia Olga Hospital, Athens; Prince of Wales Hospital, Sydney


Introduction: Acute leukaemia

Year:

Session type:

Tony Green1 and Tessa Holyoake2

1University of Cambridge, UK, 2University of Glasgow, UK


Title to be confirmed

Year:

Session type:

Speaker to be confirmed


Molecular genetics of T-cell acute lymphoblastic leukaemia

Year:

Session type:

Jan Cools

University of Leuven, Belgium


Introduction: Targeting mitosis

Year:

Session type:

Ashok Venkitaraman

University of Cambridge, UK


Small molecule inhibitors of mitotic progression

Year:

Session type:

Andrea Musacchio

IFOM-IEO Campus, Italy


Probing the mechanism of novel drugs targeted to mitosis in pre-clinical studies

Year:

Session type:

Robert Wilkinson

Astra Zeneca, UK


Early clinical studies with anti-mitotic agents

Year:

Session type:

Johann de Bono

The Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK


p53 prevents entry into mitosis with uncapped telomeres

Year:

Session type:

Maria Thanasoula1, Jose Miguel Escandell Planells1, Purificacon Muoz2,3, Sophie Badie1, Mara A Blasco2 and Madalena Tarsounas1

1Gray Institute for Radiation Oncology and Biology, Oxford, UK, 2Spanish National Cancer Center (CNIO), Madrid, Spain, 3Present address: Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain


Physicochemical and pharmacological determinants of the efficacy of a novel series of CDK7 inhibitors

Year:

Session type:

Maciej A Kaliszczak, Sebastian Kroll, Dean A. Heathcote, Simak Ali, Charles Coombes, Anthony GM Barrett, Matthew J Fuchter, Eric O Aboagye

Imperial College London, UK


Loss of a FOX03A-dependent cell cycle checkpoint for DNA replication origins sensitises cancer cells to CDC7 inhibitors

Year:

Session type:

Slavica Tudzarova, Matthew Trotter, Claire Mulvey, Jasminka Godovac-Zimmermann, Kai Stoeber, Gareth Williams

University College London, UK


Introduction: Upper gastrointestinal cancers

Year:

Session type:

David Cunningham

Royal Marsden Hospital, Sutton, UK


Functional genomics and proteomics in pancreatic cancer research

Year:

Session type:

Joerg Hoheisel

German Cancer Research Center (DKFZ), Heidelberg, Germany


Evidence base of prevention in upper gastrointestinal cancer

Year:

Session type:

Krish Ragunath

Wolfson Digestive Diseases Center, Nottingham University Hospitals NHS Trust, UK


Introduction: Paediatric tumours

Year:

Session type:

Pamela Kearns

University of Birmingham, UK


Does place of death from lung, colorectal, breast, and prostate cancer vary between ethnic groups?

Year:

Session type:

Victoria Coupland, Peter Madden, Ruth Jack, Henrik Mller, Elizabeth Davies

King's College London, London, UK


Minimal residual disease in acute lymphoblastic leukaemia

Year:

Session type:

Nick Goulden

Royal Hospital for Children and University of Bristol, UK


Benefit of radiotherapy dose escalation in localised prostate cancer with respect to expression of intrinsic markers of hypoxia

Year:

Session type:

Scott Morgan, Gerard McVey, Cathy Corbishley, Colin Cooper, Robert Huddart, Alan Horwich, David Dearnaley, Chris Parker

The Institute of Cancer Research, Sutton, UK


Genetics of neuroblastoma

Year:

Session type:

Peter Ambros

Children's Cancer Research Institute, Vienna, Austria


The clinical impact of fusion genes in paediatric sarcomas

Year:

Session type:

Sue Burchill

Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, UK


Malignant germ cell tumours display conserved microRNA (miRNA) profiles resulting in global changes in expression of mRNA targets

Year:

Session type:

Matthew Murray1, Harpreet Saini2, Stijn van Dongen2, Cei Abreu-Goodger2, Roger Palmer1, James Nicholson3, Anton Enright2, Nicholas Coleman1

1Medical Research Council Cancer Cell Unit, Cambridge, UK, 2EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK, 3Addenbrooke's Hospital, Cambridge, UK


Mitoxantrone, not idarubicin, significantly improves the outcome of children with ALL: result of the international randomised ALLR3 study

Year:

Session type:

Catriona Parker1, Rachel Waters2, Carly Leighton3, Ashish Masurekar1, Nick Goulden4, Anthony Moorman5, Rosemary Sutton6, Tom Revesz7, Phil Ancliff4, Mary Morgan8, Phil Darbyshire9, Vaskar Saha1

1University of Manchester, UK, 2University of Oxford, UK, 3Queen Mary University, UK, 4Great Ormond Street Hospital, London, UK, 5Northern Institute for Cancer Research, Newcastle, UK, 6Children's Cancer Institute Australia for Medical Research, Randwick, Australia, 7Children, Youth and Women's Health Service, Adelaide, Australia, 8Southampton General Hospital, UK, 9Birmingham Children's Hospital, UK


Rac2 and asparaginyl endopeptidase regulates invasion in pre-B acute lymphoblastic leukaemia

Year:

Session type:

Seema Alexander1, Mark Holland1, Shekhar Krishnan1, Clare Dempsey1, Tom Southgate2, Duncan Smith3, Yvonne Connolly3, Michael Walker4, Danny Bitton5, Crispin Miller5, Naina Patel1, Jizhong Liu1, Ashish Masurekar1, Anthony Whetton4, Vaskar Saha1

1CRUK Children's Cancer Group, Paterson Institute of Cancer Research, Manchester, UK, 2Immunology Group, PICR, Manchester, UK, 3Molecular Biology Core Facility, PICR, Manchester, UK, 4Stem Cell and Leukaemia Proteomics Group, PICR, Manchester, UK, 5Applied Computational Biology and Bioinformatics Group, PICR, Manchester, UK


Introduction: PET Imaging

Year:

Session type:

Paul Marsden

Guys, Kings and St Thomas School of Medicine, London, UK


Basic principles and instrumentation for positron emission tomography

Year:

Session type:

Sibylle Ziegler

Technical University of Munich, Germany


Positron emission tomography – but not fludeoxyglucose

Year:

Session type:

Stefano Fanti

University of Bologna, Policlinico, Italy


Non-invasive tracer techniques to characterize angiogenesis

Year:

Session type:

Roland Haubner

University of Innsbruck, Austria


Developments in imaging hypoxia: new tracers and data modelling

Year:

Session type:

Rehan Ali, Rebekka Hueting, Martin Christlieb

University of Oxford, UK


A method for quantifying the kinetics of hypoxia tracers using multicellular tumour spheroids

Year:

Session type:

Catherine Kelly, Eric Bernhard, Mike Brady, Ruth Muschel

University of Oxford, UK


Using mathematical modelling to gain new insights into how tumour cells respond to hypoxia-selective PET tracers

Year:

Session type:

Rehan Ali, Cat Kelly, Alex Fletcher, Sam DiSouza, Michael Brady, Martin Christlieb

University of Oxford, UK


The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts tamoxifen response

Year:

Session type:

Darran O'Connor1, Donal Brennan1, Henriette Laursen1, Sharon McGee1, Sarah McCarthy1, Elton Rexhepaj1, Michael J Duffy3, Aedin Culhane7, Stephen Hewitt2, Finian Martin1, Goran Landberg4, Lisa Ryden4, Rene Bernards6, Robert Millikan5, Karin Jirstrom4, William Gallagher1

1University College Dublin, Conway Institute, Dublin, Ireland, 2National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA, 3St. Vincent's University Hospital, Dublin, Ireland, 4Lund University, Malmo, Sweden, 5University of North Carolina, Chapel Hill, North Carolina, USA, 6Netherlands Cancer Institute, Amsterdam, Netherlands, 7Dana Farber Cancer Institute, Boston, Massachusetts, USA


Factors influencing adjuvant treatment choices in stage I seminoma: the patients perspective

Year:

Session type:

Alison Young, Jaishree Bhosle, Johnathon Joffe, Daniel Stark, Sue Rodwell, Gemma Glover, John Chester

St James's Institute of Oncology, Leeds, UK


Anti-stem cell factor enhances the effect of Anthracycline and Taxane chemotherapy in chemoresistant breast cancer cell lines

Year:

Session type:

Neil Jelly, Issam Hussain, Suebwong Chuthapisith, Jenny Eremin, Oleg Eremin, Mohamed El-Sheemy

University of Lincoln, UK


Combining peptide vaccination with immunostimulatory monoclonal antibodies provides potent immunotherapy in neuroblastoma

Year:

Session type:

Juliet Gray, Martin Glennie

University of Southampton, UK


Association of Helicobacter pylori vacA genotype with gastric cancer in northern Iran

Year:

Session type:

Farhad Mashayekhi, Zivar Salehi, Rasoul Zahmatkesh

University of Guilan, Rasht, Iran


Host-viral epigenetic interactions in HPV16-mediated oropharyngeal cancer

Year:

Session type:

Richard Shaw, Anastasia Filia, Janet Risk, Terry Jones, Triantafillos Liloglou

University of Liverpool, UK


Introduction: Lung cancer

Year:

Session type:

Michael Cullen

Queen Elizabeth Hospital, Birmingham, UK


Video-assisted thoracic surgery: its place in lung cancer management

Year:

Session type:

Aman S Coonar

Papworth Hospital, Cambridge, UK


Targeted therapy for advanced NSCLC: two steps forward and one step back?

Year:

Session type:

Frances Shepherd

Princess Margaret Hospital, Toronto, Canada


Biomarkers and the future of chemotherapy in non-small cell lung cancer

Year:

Session type:

Jean-Charles Soria

Institut de Cancrologie Gustave Roussy, Paris, France


The financial costs and consequences of cancer for patients and their families: a postal survey of patients with breast, lung, and prostate cancer in Ireland

Year:

Session type:

Aileen Timmons1, Linda Sharp1, Anne-Elie Carsin1, Noeleen Donnelly2, Joan Kelly2, John McCormack2, Niamh Ni Chonghaile2, Eileen O'Donnell3, Olywn Ryan2, Harry Comber1

1National Cancer Registry Ireland, Cork, Ireland, 2Irish Cancer Society, Dublin, Ireland, 3St Vincent's Hospital, Dublin, Ireland